TacticScaleWhat AbbVie Does & How It Makes Money (ABBV)
Updated October 2026 · reflects AbbVie's latest reported financials
Biopharmaceutical company making immunology, cancer, neuroscience, eye care and aesthetics medicines. AbbVie makes money by selling its branded prescription medicines to healthcare systems and patients worldwide.
How AbbVie makes money
AbbVie makes money by selling its branded prescription medicines to healthcare systems and patients worldwide. It also earns revenue from aesthetic products such as injectables and skincare, and from eye care products.
What AbbVie does
AbbVie is a research-based biopharmaceutical company headquartered in North Chicago, Illinois, and incorporated in 2012. Its largest areas are immunology, led by Skyrizi and Rinvoq for autoimmune and inflammatory diseases, and oncology, which includes Imbruvica and Venclexta for blood cancers, Elahere, Epkinly for lymphoma, and Emrelis for lung cancer. Outside those two areas, AbbVie sells neuroscience drugs (Vraylar for schizophrenia, bipolar disorder and depression; Ubrelvy and Qulipta for migraine; Duodopa and Vyalev for Parkinson's; and Botox Therapeutic), eye care products such as Ozurdex, Lumigan, Alphagan and Restasis, and other medicines including Mavyret for hepatitis C, Creon and Linzess. Its aesthetics business, which includes Botox Cosmetic, Juvederm fillers, body contouring and skincare, gives it a consumer-facing source of revenue alongside its prescription drugs.
Products & services
- Skyrizi
- Rinvoq
- Botox (Therapeutic & Cosmetic)
- Vraylar
- Venclexta
- Juvederm Collection
What is AbbVie worth?
On an owner-earnings DCF, AbbVie's most-likely value is about $261 versus a recent price near $276 (5% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$117) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Amgen (AMGN) · Bristol-Myers Squibb (BMY) · Viatris (VTRS) · Biogen (BIIB) · Abbott Laboratories (ABT)